Emerging Capital Ltd.
Emerging Capital Limited (FSX:EDO): Information Regarding Subsidiary MYSY for Production of First 100 Devices in the First Quarter of 2016.
DGAP-News: Emerging Capital Ltd. / Key word(s): Miscellaneous/Agreement 2016-01-15 / 20:04 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Emerging Capital Limited (FSX: EDO) ("Emerging") is pleased to announce, that it's subsidiary MYSY Ltd. ("MYSY"), In the first quarter of 2016, will produce the first 100 devices (70 Integra, 30 Simply), for INTEGRA and introduce it into the market for the first time and also to start SIMPLY clinical tests concerning ISO Certification. Using DermaPhoresis technology, MYSY has developed a non-invasive medicinal delivery device that provides regenerative rehabilitation therapy with instant pain relief. This device, called Integra (Veicolatore Molecular Intradermal), can be considered a virtual syringe (needleless), which carries the drug molecules, mixed with a gel carrier to target precise areas of the body. This way of administration drastically lowers the dispersion in the rest of the body. Usually the dispersion of the active medicine in the body by conventional methods is up to 95%, using Integra, the dispersion is reduced to up to 5% only, ensuring that the treatment targets the problem areas. The Integra is able to easily reach a depth of penetration up to 10 cm, and thicknesses of concentration up to 4 cm. Integra delivers active pharmaceutical ingredients (API) and active medicines through the skin beyond the limits of classic transcutaneous methods. Integra provides a transdermal molecular transport at low frequency due to the gel mixture, which maintains contact between the molecule and the patient's skin. Whatever principle, provided that it's water-soluble, is conveyed through the gel directly on the epidermis. The set of physical processes that occur affect the polarizability activating through the channels within, which penetrate the actual molecules of interest. As demonstrated by many studies, Integra technology is effective at increasing bone formation and bone density, healing fractures, recovery from wounds and trauma, graft and post-surgical behavior, tendonitis, osteoarthritis, backache and any disease associated with muscle and skeleton system. For further information, please contact: ========================================== INVESTOR AND MEDIA RELATIONS LINDA KIRKLAND info@emergingcapitalltd.com www.emergingcapitalltd.com ABOUT EMERGING CAPITAL LIMITED Emerging Capital Limited is listed on NSX, Australia with ticker symbol ECL and on Frankfurt, Germany with ticker symbol EDO. The primary investment objective of the Company is to develop as an aggressive investment and transaction oriented business focused on wealth creation for its shareholders. The main investment activities of the Company are expected to focus on small to medium sized enterprises that are suitable for future listing on recognised stock exchanges and may require further working capital, development assistance and/or management to realize their respective potential. --------------------------------------------------------------------------- 2016-01-15 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de ---------------------------------------------------------------------------
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found